Health written question – answered at on 7 March 2012.
To ask the Secretary of State for Health
(1) what (a) pharmacological treatments and (b) associated indications which the National Institute for Health and Clinical Excellence (NICE) has recommended for cancer treatment through either single of multiple technology appraisals since NICE was established;
(2) what (a) pharmacological treatments and (b) associated indications the National Institute for Health and Clinical Excellence has recommended for cancer treatment under the end of life criteria since the criteria was introduced in 2009;
(3) what (a) pharmacological treatments and (b) associated indications the National Institute for Health and Clinical Excellence has not recommended for cancer treatment since it was established;
(4) what (a) pharmacological treatments and (b) associated indications the National Institute for Health and Clinical Excellence has recommended for (a) prostate cancer, (b) lung cancer, (c) bowel cancer, (d) breast cancer and (e) kidney cancer through (i) single or multiple technology appraisals and (ii) under the end of life criteria since it was established;
(5) if he will publish the final calculated cost per quality adjusted life year of each pharmacological treatment and associated indications which the National Institute for Health and Clinical Excellence (NICE) has not recommended for cancer treatment since NICE was established;
(6) if he will publish the final calculated cost per quality adjusted life year of each pharmacological treatment and associated indications which the National Institute for Health and Clinical Excellence (NICE) has recommended for cancer treatments; and which such treatment and indications have been recommended for cancer treatment under the end of life criteria since NICE was established;
(7) if he will publish the determined population size for each pharmacological treatment and associated indications which the National Institute for Health and Clinical Excellence (NICE) has recommended for cancer treatment under the end of life criteria since NICE was established;
(8) if he will publish the determined population size for each pharmacological treatment and associated indications which the National Institute for Health and Clinical Excellence has recommended for cancer treatment since it was established.
The information requested is not held by the Department. I have asked the chief executive of the National Institute for Health and Clinical Excellence to write to the hon. Member with this information. A copy will be placed in the Library.
Yes0 people think so
No1 person thinks not
Would you like to ask a question like this yourself? Use our Freedom of Information site.